Biotinylated Human TIGIT, Fc,Avitag (MALS verified) (TIT-H82F1) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1-1).
Predicted N-terminus: Met 22
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 41.3 kDa. As a result of glycosylation, the protein migrates as 45-55 kDa under reducing (R) condition, and 85-115 kDa under non-reducing (NR) condition (SDS-PAGE).
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human TIGIT, Fc,Avitag (MALS verified) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Biotinylated Human TIGIT, Fc,Avitag (MALS verified) (Cat. No. TIT-H82F1) was more than 85% and the molecular weight of this protein is around 95-115 kDa verified by SEC-MALS.
Immobilized Human CD155, Fc Tag (Cat. No. CD5-H5251) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) with a linear range of 10-156 ng/mL (QC tested).
Serial dilutions of Human TIGIT Neutralizing antibody were added into Human CD155, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD5-H5254): Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.08116 μg/mL (Routinely tested).
Serial dilutions of Human TIGIT Neutralizing antibody were added into Human CD155, Fc Tag (Cat. No. CD5-H5251): Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.06065 μg/mL (Routinely tested).
FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.